百济神州:开创性肿瘤平台 行业标准制定者

中国国际金融股...
30 Jun

公司近况6 月26 日,公司在投资者研发日活动中,展示了独特的研发战略、领先的血液瘤布局、以及广泛的实体瘤管线。评论研发战略:全球运营,新分子实体快速发展。2024 年公司将10 个自主研发的新分子实体推向临床阶段,相比于2022/2023 年的3/5 个明显增加,涉及到小分子/CDAC/双(三)抗/ADC等多个前沿技术平台。公司继续沿用了百悦泽的成功开发经验,多管线并行创新,唯优质分子推向临床,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10